Dieter MD - Enzo Biochem Chief Labs
| ENZ Stock | USD 0.97 0.02 2.02% |
Insider
Dieter MD is Chief Labs of Enzo Biochem
| Age | 61 |
| Address | 21 Executive Blvd, Farmingdale, NY, United States, 11735 |
| Phone | 631 755 5500 |
| Web | https://www.enzo.com |
Enzo Biochem Management Efficiency
The company has Return on Asset of (0.0744) % which means that on every $100 spent on assets, it lost $0.0744. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.1459) %, meaning that it generated no profit with money invested by stockholders. Enzo Biochem's management efficiency ratios could be used to measure how well Enzo Biochem manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.29 in 2024. Return On Capital Employed is likely to drop to -0.17 in 2024. At this time, Enzo Biochem's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 7.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 14.9 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Nadia Altomare | Sera Prognostics | 53 | |
| RN RN | Castle Biosciences | 56 | |
| Kevin Theriault | Sotera Health Co | N/A | |
| Charles IV | Psychemedics | 58 | |
| Kara Thornton | Neuronetics | N/A | |
| Andrew Macan | Neuronetics | 51 | |
| Paul Beresford | Biodesix | N/A | |
| Zhihong Zhang | Burning Rock Biotech | 48 | |
| MD FACR | Exagen Inc | N/A | |
| Matt Stauffer | Biodesix | N/A | |
| Paul Kearney | Sera Prognostics | 56 | |
| Ryan Douglas | Exagen Inc | N/A | |
| Michael Petras | Sotera Health Co | 55 | |
| Gary Pestano | Biodesix | 57 | |
| MingChou Lee | Exagen Inc | N/A | |
| Bobbi Coffin | Biodesix | N/A | |
| Shaokun Chuai | Burning Rock Biotech | 45 | |
| Michael Biehl | Sotera Health Co | 68 | |
| Richard Anderson | DarioHealth Corp | 55 | |
| Lehmann JD | Sotera Health Co | 56 | |
| Stephen MS | Neuronetics | 60 | |
Management Performance
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0744 |
Enzo Biochem Leadership Team
Elected by the shareholders, the Enzo Biochem's board of directors comprises two types of representatives: Enzo Biochem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enzo. The board's role is to monitor Enzo Biochem's management team and ensure that shareholders' interests are well served. Enzo Biochem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enzo Biochem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dieter MD, Chief Labs | ||
| Hamid Erfanian, Chief Executive Officer, Director | ||
| Barry Weiner, President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director | ||
| Mary Tagliaferri, Lead Independent Director | ||
| Dov Perlysky, Lead Independent Director | ||
| Bruce Dey, Vice President - Sales and Marketing of Enzo Clinical Labs | ||
| Ian Walters, Independent Director | ||
| Matthew Kupferberg, General Secretary | ||
| David Bench, Chief Financial Officer, Senior Vice President, Treasurer, Corporate Secretary | ||
| Peter Clemens, Director | ||
| Brian Fisher, General Counsel | ||
| Bruce Hanna, Independent Director | ||
| Patricia CPA, Interim Officer | ||
| Rebecca Fischer, Independent Director | ||
| Elazar Rabbani, Chairman of the Board, Chief Executive Officer, Secretary | ||
| Fabian Blank, Director | ||
| Bradley Radoff, Independent Director | ||
| Dieter Schapfel, Chief Medical Director of Enzo Clinical Labs | ||
| Kara Cannon, Corporate Vice President - Commercial Operations |
Enzo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enzo Biochem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0744 | ||||
| Profit Margin | (0.82) % | ||||
| Operating Margin | (0.39) % | ||||
| Current Valuation | 2.71 M | ||||
| Shares Outstanding | 52.24 M | ||||
| Shares Owned By Insiders | 23.72 % | ||||
| Shares Owned By Institutions | 32.04 % | ||||
| Number Of Shares Shorted | 477.48 K | ||||
| Price To Earning | 26.60 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Enzo Stock Analysis
When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.